Research Briefs: DMD, BMD Trials Update

Investigators are testing compounds designed to cause exon skipping in Duchenne MD and drugs that may increase blood flow in Duchenne and Becker MD

Article Highlights:
  • The launch of a trial of exon-skipping drug eteplirsen in DMD in Ohio has been delayed.
  • Prosensa continues to develop new exon-skipping compounds for DMD.
  • Tadalafil and sildenafil are being tested in DMD and BMD.
by Margaret Wahl on June 21, 2011 - 9:08am

U.S. trial of eteplirsen for Duchenne MD delayed

AVI BioPharma of Bothell, Wash., announced June 9, 2011, that the launch of its phase 2 trial of eteplirsen (pronounced eh-TEHP-lur-son; formerly called AVI4658) in Duchenne muscular dystrophy (DMD) at Nationwide Children's Hospital in Columbus, Ohio, has been delayed, following a request by the institutional review board for a revision to the study design.

The trial had been slated to start in late spring 2011.

AVI says the requested change is not related to either safety or the expected activity of eteplirsen, and that the company expects to submit a revised plan to the institutional review board later in June 2011.

Eteplirsen is an experimental exon-skipping drug designed to coax cells to ignore (skip) the exon 51 section of the dystrophin gene and make a functional dystrophin protein, which is needed in DMD. Phase 1-2 trials of the compound conducted in the United Kingdom have been promising.

See also:

Editor's note 7/28/11: The eteplirsen (AVI-4658) trial is now open at Nationwide Children's Hospital in Columbus, Ohio. See Eteplirsen (AVI-4658) Boosts Dystrophin Production in DMD.

Prosensa continuing to develop DMD exon-skipping drugs

The biopharmaceutical company Prosensa, based in Leiden, the Netherlands, has provided an update on its development of exon-skipping compounds for DMD.

The company is conducting a clinical trial of PRO044 (now closed to recruitment) in Belgium, Italy, the Netherlands and Sweden. PRO044 is designed to coax cells to skip the exon 44 section of the dystrophin gene and produce a functional dystrophin protein, which is needed in DMD.

About Clinical Trials

A clinical trial is a test, in humans, of an experimental treatment. Although it's possible that benefit may be derived from participating in a clinical trial, it's also possible that no benefit, or even harm, may occur. MDA has no ability to influence who is chosen to participate in a clinical trial. To learn more, see Understanding Clinical Trials and Being a Co-Adventurer, which is about neuromuscular disease clinical trials.

Prosensa is also developing molecules designed to coax skipping of exons 45, 53, 52 and 55. These are at the preclinical (laboratory) stage.

PRO051/GSK2402968, in development jointly by Prosensa and pharmaceutical company GlaxoSmithKline, is being tested in clinical trials and is designed to cause skipping of exon 51 of the dystrophin gene. In April 2011, it was reported that this drug resulted in dystrophin protein production and increased walking distance in a 48-week trial conducted in Belgium and Sweden.

A phase 1 safety trial of PRO051/GSK2402968 is under way in Ohio and France. A phase 2 clinical trial and a phase 3 clinical trial are taking place outside the United States.

Tadalafil, sildenafail being tested in Duchenne, Becker MD

A trial at Cedars-Sinai Medical Center in Los Angeles will test tadalafil and sildenafil in DMD. Investigators are recruiting participants who are 7-15 years old, able to walk and meet other study criteria.

Participants will be randomly assigned to receive either tadalafil or sildenafil, which have been shown to improve muscle blood flow in a mouse model of DMD.

A separate trial, also at Cedars-Sinai, is seeking participants with Becker muscular dystrophy (BMD) for a trial of tadalafil. That trial is being supported by MDA.

See also Tadalafil in Becker MD and Enhancing Blood Flow to Exercising Muscles.

Your rating: None Average: 3 (3 votes)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email See comment policy